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INTRODUCTION 
 
Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered autologous T-cells 
has achieved unprecedented efficacy in the treatment of patients with refractory B-cell 
malignancy.1-3 In this context, the CD19 molecule provides a target par excellence, since toxicity 
arising from the depletion of healthy B-cells can be mitigated with immunoglobulin replacement 
therapy. However, solid tumors present several additional hurdles to the development of 
effective CAR T-cell immunotherapy. Unlike B-cell malignancy, lineage-restricted molecules 
are generally unsuitable for targeting owing to their expression at high levels by one or more 
critical organs. Broadly speaking, two alternative approaches warrant consideration. First, tumor-
specific mutations (eg epidermal growth factor receptor variant III) provide attractive 
opportunities for immunotherapy of selected cancers.4,5 However, target expression is sporadic, 
subject to intra-tumoral heterogeneity and downregulation upon disease relapse.6,7 Alternatively, 
targeting may be directed against molecules that are over-expressed on transformed cells relative 
to healthy tissue, such as ErbB2. While initial clinical testing resulted in lethal toxicity,8 more 
recent evaluation of this strategy has demonstrated that an efficacy signal can be achieved safely 
using CAR+ T-cells.9 This provides a strong rationale for the identification and validation of 
additional targets that are not absolutely tumor specific, but which are strongly upregulated on 
transformed cells and contribute to disease pathogenesis. 
 
One such candidate is the epithelial-specific integrin, αvβ6. Cell surface expression requires 
pairing of the monogamous β6 chain with the more promiscuous αv partner.10 αvβ6 is commonly 
over-expressed in solid tumors derived from pancreas, head and neck, skin, lung, esophagus, 
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stomach, colon, breast, uterine cervix and fallopian tube/ovary and is generally associated with 
worsened prognosis.11-17 In keeping with this, αvβ6 activates pro-transforming growth factor-β 
and promotes epithelial to mesenchymal transition, cellular migration and matrix 
metalloproteinase activity.18-21 By contrast, this integrin is minimally expressed in adult tissue, 
except during wound healing.17,22 In light of these attributes, αvβ6 has attracted significant 
interest as a target for antibody-based imaging and treatment of many cancer types.14,23,24  
 
Infection of several species by the foot and mouth disease virus (FMDV) is mediated by the 
ability of the viral protein 1 coat protein to bind to a number of integrins, including αvβ6.25 A 
derived 20mer peptide (A20FMDV2) has been characterized as an effective antagonist of αvβ626 
and has been used to image αvβ6-positive tumors.27 We hypothesized that this 20mer would 
represent a suitable moiety to engineer an αvβ6–targeted CAR since it contains two overlapping 
αvβ6-binding motifs (RGD and DLXXL) and binds with >1000-fold greater specificity to this 
integrin than to other family members, such as αvβ3, αvβ5 and α5β1.13,28 Using A20FMDV2 as a 
targeting moiety, we describe for the first time the development of an αvβ6-specific CAR that 
elicits potent therapeutic activity against diverse solid tumor types, without significant toxicity. 
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RESULTS  
 
αvβ6 integrin is expressed by cell lines derived from multiple solid tumors  
 
Supplementary Figure S1 shows αvβ6 expression by the panel of human tumor cells used in 
this study. High-level expression (100% positive; geometric mean fluorescence intensity 
(MFI)>2000) was found in pancreatic ductal adenocarcinoma (PDAC) cell lines (Panc0403, 
BxPC3), in BT20 triple negative breast cancer (TNBC) cells and in the clear cell epithelial 
ovarian carcinoma (EOC) cell line, OVSAYO. Intermediate expression (MFI 1000–2000) was 
observed in the PDAC cell line, CFPAC1, the TNBC cell line MDA-MB-468 and in the SKOV-
3, OVMANA, TUOC1 and OVTOKO EOC cell lines. Lower expression (MFI 150-999) was 
detected in luminal (T47D, MCF7, ZR75) and luminal/ HER2+ (BT474) breast cancer cells and 
in the OVSAHO, HAC2, SMOV2, OVAS and KK EOC cell lines. Minimal expression 
(MFI<150; <9%+ events) was found in the PDAC cell line Panc-1, the TNBC cell line CAL51, 
and in the A2780, A2780CP, Kuramochi and TOV21G EOC cell lines. 
 
Comparison of in vitro anti-tumor activity of candidate αvβ6-targeted CARs  
 
To engineer candidate αvβ6 CARs, the A20FMDV2 peptide (A20)26 or a phage display-derived 
12mer peptide (B12)29 were fused to a human CD28 spacer (from amino acid 114, in which 
MYPPPY was replaced by a 9e10 myc tag), followed by a CD28+ transmembrane/endodomain 
and CD3ζ endodomain. CARs were named A20-28z and B12-28z and contain two or one αvβ6 
binding sites respectively (Figure 1a-b). A scrambled derivative of A20 (C20, in which RGDL 
is replaced by AAAA; Figure 1a) or truncated CD28 endodomain (Figure 1c) were used to 
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create control CARs (named C20-28z and A20-Tr respectively)30 (Figure 1b-c). CARs were 
stoichiometrically co-expressed using a Thosea Asigna (T)2A peptide-containing vector with a 
chimeric cytokine receptor 4αβ (Figure 1d) to enable preferential expansion of αvβ6-re-targeted 
T-cells ex vivo. All CARs were delivered to human T-cells using the SFG retroviral vector 
(Figure 1e). 
 
To compare function, human CAR T-cells were co-cultivated with PDAC tumor cells that 
naturally express minimal (min; Panc-1), intermediate (CFPAC1) or high levels of αvβ6 
(Panc0403, BxPC3). A20-28z+ T-cells released large quantities of interferon (IFN)- when co-
cultivated with αvβ6+ PDAC cells, accompanied by tumor cell killing, monolayer destruction 
and enrichment of transduced T-cells following CAR stimulation (Supplementary Figure S2). 
By contrast, cytotoxic activity of B12-28z+ T-cells, was minimal or absent and was 
unaccompanied by reproducible cytokine release or CAR T-cell enrichment following 
stimulation (Supplementary Figure S2 and data not shown).  
 
In light of these findings, A20-28z was advanced and B12-28z was discarded. Specificity of 
integrin targeting was evaluated in cytotoxicity assays using A375 cells that naturally express 
several RGD-binding integrins, including αvβ3, αvβ5, αvβ8 and α5β1 but not αvβ6 (Figures 1f 
and 1g).24 Comparison was made with cytotoxicity against a β6+ A375 derivative (Figure 1g). In 
an extended cytotoxicity assay that lasted 1 – 7 days, A20-28z+ T-cells killed β6+ but not control 
A375 cells (Figure 1h), accompanied by β6-dependent IFN-γ release (Figure 1i). As expected, 
neither A20-Tr+ nor C20-28z+ T-cells demonstrated cytotoxic activity in these assays. In order to 
further characterise the specificity of the A20 peptide, its binding capacity for other integrins was 
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also assessed. Addition of increasing amounts of biotinylated A20 peptide led to proportionately 
greater binding to both A375 β6 cells (Figure 1j) and to recombinant αvβ6 (Figure 1k). By 
contrast, the A20 peptide did not exhibit any detectable binding to A375 puro cells or to other 
RGD-binding integrins (Figure 1j-k).  
 
Expansion of αvβ6 re-targeted T-cells using interleukin-4 
 
To preferentially expand αvβ6-re-targeted T-cells ex vivo, CARs were stoichiometrically co-
expressed using a Thosea Asigna (T)2A peptide-containing vector with 4αβ (Figure 1e). The 
4αβ chimeric cytokine receptor comprises the human IL-4 receptor-α ectodomain which has been 
fused to the shared human IL-2/ IL-15 receptor β transmembrane and endodomain regions. 
Binding of the poorly mitogenic cytokine IL-4 leads to the delivery of a potent and selective 
growth signal in 4αβ+ T-cells.31 Consequently, all 4αβ+ CAR T-cell populations underwent 
selective enrichment and expansion when cultured in IL-4 (Supplementary Figure S3a). 
Addition of exogenous IL-4 significantly increased cytotoxicity of A20-28z/4αβ T-cells against 
BxPC3 cells in vitro (Supplementary Figure S3b), accompanied by a non-significant trend 
towards increased IFN- release (Supplementary Figure S3c). Neither the co-expression of 4αβ 
nor the addition of IL-4 resulted in an alteration in the proportion of CAR T-cells with naïve 
(CCR7+CD45RO-), central memory (CCR7+CD45RO-), effector memory (CCR7-CD45RO+) or 
effector (CCR7-CD45RO-) phenotype, when compared to cells cultured in IL-2 (Supplementary 
Figure S3d). 
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αvβ6-retargeted CAR T-cells elicit broad anti-tumor activity in vitro 
 
Following IL-4-mediated expansion in vitro, A20-28z/4αβ+ and control C20-28z/4αβ + or A20-
Tr/4αβ+ T-cells were evaluated for anti-tumor activity using a panel of cell lines that express 
varying levels of αvβ6. Unlike controls, A20-28z+ T-cells killed αvβ6+ PDAC, HER2 amplified 
breast, luminal breast, TNBC and ovarian tumor cells (Figure 2a-e), accompanied by release of 
IL-2 (Figure 3) and IFN- (Supplementary Figure S4). Residual tumor cell viability and 
cytokine release correlated inversely or directly (respectively) with intensity of αvβ6 expression 
on target cells (Figure 4). Importantly however, tumor cells that expressed very low levels of 
αvβ6 (eg Panc-1; Figure 2a or CAL51; Figure 2d) were not killed.  
 
avβ6 re-targeted CAR T-cells cause regression of several tumor xenografts with minimal 
toxicity  
 
Firefly luciferase (fluc)+ SKOV-3 cells express αvβ6 and can be propagated as an intraperitoneal 
(i.p.) xenograft that is amenable to monitoring using bioluminescence imaging (BLI).32 
Consequently, this provides a convenient model to test in vivo anti-tumor activity of adoptively 
transferred αvβ6 re-targeted CAR T-cells. To permit T-cell imaging, co-transduction was 
performed with A20-28z/4αβ (or the control A20-Tr/4αβ retroviral vector) and a second 
retroviral vector that encodes for green fluorescent protein (GFP) and red-shifted Renilla 
luciferase (rluc; Figure 1l). After IL-4-mediated ex vivo enrichment for CAR T-cell expression, 
transduced T-cells were analysed for expression of CD8 and retroviral-encoded transgenes 
(Figure 5a). Functionality of CAR T-cells was confirmed in vitro using cytotoxicity and 
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cytokine release assays (data not shown) prior to i.p. transfer into SCID Beige mice with 
established SKOV-3 ffluc xenografts.   
 
Mice treated with control A20-Tr/4αβ/rluc/GFP+ CAR T-cells or PBS had progressive disease. 
By contrast, mice treated with A20-28z/4αβ/rluc/GFP+ CAR T-cells exhibited tumor regression 
within 5 days of treatment and maintained a significantly lower tumor burden than either control 
group (Figure 5b-c). Treatment with αvβ6-retargeted CAR T-cells significantly extended 
median survival from 63 days (both control groups) to 82 days (A20-28z group; p = 0.0014) 
(Supplementary Figure S5). Although the A20-28z CAR can also recognize αvβ6 expressed by 
murine cells, treatment was very well tolerated. Minimal weight loss (<5%) was observed in 
some mice, with complete resolution within 1 week (Figure 5d). This contrasts with severe 
weight loss and cytokine release syndrome (CRS) that may be induced in the same tumor 
xenograft model using ErbB retargeted CAR T-cells.33  
 
To investigate the generality of these findings, similar experiments were performed in which 
BxPC3 (Figure 6), MDA-MB-468 (Figure 7) or Panc0403 (Figure 8) tumor xenografts were 
established in SCID Beige mice. As before, T-cells were dual transduced to co-express rluc/GFP 
with A20-28z/4αβ or A20-Tr/4αβ and enriched for CAR+ T-cells by ex vivo culture in IL-4. Prior 
to adoptive transfer, T-cells were analysed for transgene expression (Figure 6a, 7a, 8a) and for 
in vitro cytotoxicity and cytokine release following co-culture with αvβ6+ tumor cells (data not 
shown). In all cases, mice treated with either PBS or A20-Tr/4αβ/rluc/GFP+ T-cells 
demonstrated similar levels of tumor progression whereas A20-28z/4αβ/rluc/GFP+ CAR T-cells 
caused significant tumor regression (BxPC3 – Figure 6b-c; MDA-MB-468 – Figure 7b-c) or 
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stabilization (Panc0403 - Figure 8b) followed by delayed disease progression. Tumor regression 
was observed in the Panc0403 model in a second experiment, following treatment with A20-28z+ 
T-cells (Supplementary Figure S6). Anti-tumor activity of αvβ6-retargeted CAR T-cells was 
associated with transient minor and fully reversible weight loss (Figure 6d, 7d, 8c).  
 
T-cell imaging demonstrates inadequate longevity of human CAR T-cells in SCID Beige 
mice 
 
Engineering of CAR T-cells to co-express rluc/GFP allowed serial monitoring of the bio-
distribution of CAR T-cells using BLI. It also provides quantitative information since we found 
that the number of CAR T-cells present correlated directly with total flux (Supplementary 
Figure S7). Renilla luciferase utilizes a different substrate (coelenterazine) than ffluc (d-
luciferin), which is expressed by tumor cells in these models, allowing separate imaging of T-
cells and tumor in the same animals. Using this approach, we found that incomplete eradication 
of tumor burden correlated with progressive loss of CAR T-cells following adoptive transfer, 
although a small residual population of CAR T-cells was frequently detected (Panc0403 model; 
Figure 8d). Similar results were obtained in the SKOV-3 and BxPC3 models (data not shown). 
Administration of exogenous IL-4 exerted only a marginal impact on therapeutic activity when 
limiting numbers of CAR T-cells were used to treat mice with advanced tumor burden 
(Supplementary Figure S8a). This was accompanied by a non-significant trend towards 
delayed loss of CAR T-cells in mice treated with high-dose IL-4 (Supplementary Figure S8b). 
Combination treatment with CAR T-cells and IL-4 was not toxic, indicated by lack of weight 
loss in treated mice (Supplementary Figure S8c). 
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Human CAR T-cells recognize mouse αvβ6 but cause mild, transient and fully reversible 
toxicity at supra-therapeutic dose levels  
 
The FMDV 20mer also binds mouse αvβ6 with high affinity.28 To test if human A20-28z+ T-
cells engage the mouse αvβ6 ortholog, co-cultivation experiments were performed using 4T1 
mammary tumor cells, which naturally express this integrin (data not shown). Unlike control T-
cells, human A20-28z+ T-cells destroyed 4T1 tumor cells, accompanied by release of IFN- 
(Supplementary Figure S9 and data not shown). 
 
We have previously shown that CAR T-cells delivered using the i.p. route remain largely in the 
peritoneal cavity.34 Nonetheless, they can trigger severe macrophage-dependent cytokine release 
syndrome (CRS), particularly in the presence of advanced tumor burden.33 Such toxicity was not 
seen in the tumor xenograft models presented above. However, i.p. delivery may not permit 
human CAR T-cells to access all sites where αvβ6 is naturally expressed in mice, notably 
gastrointestinal epithelium.28 Consequently, we performed a study in which bolus doses of CAR 
T-cells were administered i.v. to these animals. A single dose of 20 x 106 CAR T-cells resulted in 
no weight loss or other clinical manifestations of toxicity. By contrast, when 40 x 106 A20-
28z/4αβ+ T-cells were administered in two divided doses over 24 hours, significant weight loss 
was observed which was transient and fully reversible. Toxicity was dependent on an intact CAR 
since it was not observed with T-cells that expressed the truncated A20-Tr control 
(Supplementary Figure S10). 
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DISCUSSION 
 
Aberrant expression of the epithelial-specific integrin αvβ6 is prevalent in several cancers.11-16,18 
The pro-invasive effect of αvβ6 is most graphically illustrated by its predominant expression at 
the infiltrating margin of the tumor mass.11 By contrast, expression of this integrin is scarcely 
detectable in healthy human tissues,17,22 rendering it a highly attractive candidate for 
immunotherapeutic targeting. Here, we show for the first time that T cells engineered to express 
an αvβ6-specific CAR mediate therapeutic activity against a broad range of solid tumor types, 
both in vitro and in vivo. 
 
To engineer candidate αvβ6-targeted CAR T-cells, two integrin-binding peptides were coupled 
to matched hinge, transmembrane and CD28+CD3 endodomain modules. The FMDV-derived 
A20 peptide has been extensively characterised for its ability to bind specifically to αvβ6 but not 
to other αv–based heterodimeric integrins. We found that T-cells engineered to express an A20-
derived CAR (A20-28z) killed tumor cell types of diverse origin, accompanied by cytokine 
release. Importantly, the magnitude of these effector activities correlated closely with cell surface 
expression of αvβ6 integrin, meaning that target cells with very low levels of αvβ6 (e.g. Panc-1, 
CAL51) were ignored. We also evaluated an alternative second generation CAR that was 
targeted using a 12mer peptide, isolated by phage display.29 The B12 peptide had been used to 
engineer a first-generation CAR to which some in vitro anti-tumor activity had been attributed.35 
However, this was demonstrated using a re-stimulated CD8+ T-cell line (isolated following 
hygromycin selection) and two derived CD8+ T-cell clones. When we re-evaluated this peptide 
in the context of a second generation CAR which was expressed in unselected primary human T-
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cells, negligible anti-tumor activity was observed. Given that the B12 peptide is shorter, it is 
possible that cognate epitope is not accessible by this very short peptide. Consequently, A20-28z 
alone was advanced for further study.  
 
In vivo efficacy of A20-28z CAR T-cells was demonstrated in four established xenograft models, 
representative of PDAC, breast and ovarian cancer. Using a dual BLI imaging strategy, we 
demonstrated that αvβ6 re-targeted A20-28z+ CAR T-cells declined progressively in the days 
following delivery. This may account for the delayed tumor relapse observed, providing a 
rationale for the exploration of repeated T-cell administration in future studies.32  
 
Prior to adoptive transfer, genetically engineered T-cells were enriched during ex vivo expansion 
since the CAR was co-expressed with 4αβ, a chimeric cytokine receptor that allows selective IL-
4-mediated proliferation of CAR T-cells.31 This approach is now in use in a Phase 1 clinical trial 
in patients with locally advanced or recurrent head and neck cancer. In that setting, a broadly 
reactive ErbB-specific CAR is co-expressed with 4αβ, allowing IL-4-mediated expansion of cell 
products prior to intra-tumoral delivery.37 This approach obviates the need for leukapheresis 
since over 2 billion CAR+ T-cells can reliably be expanded/ enriched within 2 weeks from 
120mL blood, even from patients with advanced malignancy and profound lymphopenia. To 
date, eight CAR T-cell batches have been produced in this ongoing trial that have exceeded these 
specifications, without any batch failures (data not shown). 
 
In our study, we used the 4 system as a means of in vitro expansion. However, IL-4 is also 
produced in vivo in humans, and may be overproduced in the tumor microenvironment. As 
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discussed previously,31 this could theoretically benefit anti-tumor activity but might also enhance 
toxicity of this approach. In our study, we found that provision of exogenous IL-4 cytokine 
support did not improve anti-tumor activity of CAR T-cells or their long-term survival. This may 
have been because of the very short half-life of IL-4 in vivo. Moreover, combination IL-4 and 
CAR T-cell treatment did not increase toxicity, although human IL-4 is not active in the mouse. 
 
Meaningful safety testing of human A20-28z+ CAR T-cells could be undertaken in SCID Beige 
mice for three reasons. First, the A20 FMDV targeting moiety can bind to mouse αvβ6 integrin 
with comparable affinity to the human ortholog.28 As a result, human A20-28z+ CAR T-cells also 
recognize mouse tumor cells that express this integrin. Second, we have previously shown that 
i.p. delivery of human ErbB re-targeted CAR T-cells can elicit severe CRS in SCID Beige mice, 
in a manner that is accentuated by high tumor burden. In that setting, macrophage activation (a 
functionality that is preserved in SCID Beige mice) accompanied by IL-6 release play a pivotal 
role,33 recapitulating the key role of these intermediates in human CRS.38 Third, expression of 
αvβ6 in mice is proportionately greater than in man, most notably in the gastrointestinal tract.28 
In keeping with this, laboratory mice are highly susceptible to FMDV,39 unlike man in which this 
viral illness is an extraordinarily unusual zoonosis.40 Reassuringly however, minimal toxicity 
accompanied tumor regression in all four xenograft models following treatment with αvβ6-
targeted A20-28z CAR T-cells. Administration of very large doses using the i.v. route did result 
in reversible toxicity which was dependent upon an intact αvβ6-targeted CAR.  
 
Taken together, these data justify the evaluation of αvβ6-targeted CAR T-cell immunotherapy 
for tumors in which aberrant expression of this integrin is present. We are currently developing a 
 14 
strategy for Phase 1 evaluation of this approach in patients with otherwise untreatable αvβ6-
expressing malignancy.  
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MATERIALS AND METHODS  
 
Retroviral constructs. To enable detection of CARs, a myc epitope-tagged framework was 
engineered (Figure 1b-d). A codon-optimized cDNA was synthesized to encode for human 
CD28 (amino acids 114 to 200) in which B7-binding residues 117-122 (MYPPPY) were 
substituted with residues 410-419 of human c-myc (EQKLISEEDL) (Mr Gene, Regensburg, 
Germany). The sequence was flanked by 5’ Not1 and 3’ Apa1 restriction sites and was 
substituted for the corresponding fragment in SFG T1E28z, (encodes a broadly ErbB reactive 
CAR with a CD28+CD3 endodomain).41 The resultant myc epitope-tagged CAR (Tm28z) 
exhibited comparable function to T1E28z (data not shown). Next, codon-optimized cDNAs were 
synthesized in which two candidate αvβ6-binding peptide sequences were fused to signal 
peptides selected for correct cleavage site using SignalP 3.0 server [42] (Genscript, Piscataway, 
NJ; Figure 1a). The VP1-derived A20FMDV2 20mer peptide was placed downstream of a 
CD124 signal peptide (A20).43 A control (αvβ6 non-binding) peptide was generated in which the 
RGDL motif within A20FMDV2 was substituted with AAAA (C20). To engineer an alternative 
CAR targeting moiety, a previously described αvβ6-binding 12mer peptide (isolated by phage 
display).29,35 was placed downstream of a human CD3 signal peptide (B12) (Figure 1a). All 
cDNAs were substituted for the smaller Nco1/Not1 fragment within SFG Tm28z. The resultant 
CARs were named A20-28z, C20-28z and B12-28z (Figure 1b). An endodomain truncated 
control CAR (A20-Tr) was also engineered in which the Not1/ Xho1 fragment within A20-28z 
was substituted with a smaller synthetic cDNA (Genscript) encoding CD28 residues 114-182 (in 
which MYPPPY was replaced by the myc epitope tag; Figure 1c). 
 
 16 
In most experiments, CARs were co-expressed with an IL-4-responsive chimeric cytokine 
receptor (4αβ, in which the IL-4 receptor- ectodomain is fused to the shared transmembrane/ 
endodomain of IL-2/15 receptor-; Figure 1d). T-cells that express 4αβ undergo selective 
enrichment and expansion when cultured in IL-4.31 Stoichiometric co-expression was achieved 
using an intervening furin cleavage site (RRKR), [serine-glycine]2 linker and Thosea Asigna 2A 
(T2A) peptide (Figure 1e).31 
 
To visualize T-cells in vivo, a red-shifted Renilla reniformis luciferase 8.6-535 (rluc; Genscript)44 
was co-expressed with GFP in a single SFG retroviral vector containing a furin cleavage site and 
T2A peptide (SFG rluc/GFP; Figure 1l). To visualize tumors in vivo, firefly luciferase (ffluc) 
was co-expressed with tdTomato red fluorescent protein (tdRFP; Genscript) in a single SFG 
retroviral vector containing a furin cleavage site and T2A peptide (SFG ffluc/tdTom; Figure 
1m). 
 
Culture and retroviral transduction of primary human T-cells. Blood samples were obtained 
from healthy volunteers with approval of the South East London Research Ethics Committee 1 
(reference 09/H0804/92). Activation of T-cells was achieved 48h prior to gene transfer using 
CD3+CD28-coated paramagnetic beads (1:1 bead: cell ratio; Thermo Fisher Scientific, Paisley 
UK). Gene transfer was performed using PG13 retroviral packaging cells as described.45 
Transduced T-cells were cultured in RPMI-1640 supplemented with 10% human AB serum 
(Sigma, Poole, UK), GlutaMax and antibiotic-antimycotic solution (Thermo Fisher Scientific) 
and in the presence of either 100U/ml IL-2 (Proleukin, Novartis, Frimley, UK), or 30ng/ml IL-4 
(Gentaur, Kampenhout, Belgium).  
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Cell lines. Ffluc+ Panc-1, BxPC3, ffluc+ CFPAC1, ffluc+ Panc0403, A375 puro (transduced with 
pBabe puro retrovirus), A375-β6 (transduced with pBabe puro retrovirus that encodes for human 
β6), A2780, A2780CP and TOV21G cells were obtained from the Barts Cancer Institute, Queen 
Mary University of London. Ffluc+ SKOV-3 cells were purchased from Caliper (PerkinElmer, 
Waltham MA). Kuramochi and OVSAHO cells were obtained from the Japanese Collection of 
Research Bio-resources Cell Bank. The clear cell lines OVAS, SMOV2, KK, HAC2, OVTOKO, 
OVSAYO, TUOC1 and OVMANA were a kind gift from Dr Itamochi, Tottori University School 
of Medicine, Japan. The breast cancer cell lines CAL51, BT20, MDA-MB-468, MCF7, BT474 
and ZR75-1 were obtained from the Breast Cancer Now Research Unit, King’s College London. 
Tumor cell lines were grown in R10 or D10 medium, respectively comprising RPMI or DMEM 
(Lonza, Basel, Switzerland) supplemented with 10% FBS (Sigma), GlutaMax and antibiotic-
antimycotic solution (Life Technologies). PG13 retroviral packaging cells were obtained from 
the European Collection of Cell Cultures (ECACC, Porton Down, UK) and were maintained in 
D10. H29 retroviral packaging cells were a gift from Dr. Michel Sadelain (Memorial Sloan 
Kettering Cancer Center, NY) and were propagated as described.45 All tumor cell lines were 
validated by short tandem repeat DNA profiling and experiments were performed within 30 
passages of receipt. 
 
Flow cytometry analysis. Expression of αvβ6 was detected using the 6.3G9 antibody,46 
followed by goat anti-mouse Ig-PE (Dako, Ely, UK) and was expressed as percentage positivity 
and/ or geometric mean fluorescence intensity. Cells stained with secondary antibody only 
served as a negative control. Expression of CARs was detected using supernatant derived from 
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the 9e10 hybridoma (ECACC), which binds to residues 410-419 of human c-myc, followed by 
goat anti-mouse Ig-PE. Untransduced T-cells acted as a negative control. CD8 expression was 
detected using PE-conjugated PNIM0452 (Immunotech, Marseille, France). Phenotypic analysis 
of T-cells was performed using anti-CCR7 (R&D systems FAB197F) and CD45RO (Biolegend 
304210) antibodies. In some assays, populations were gated on CAR+ cells detected using an 
antibody against CD124 (BD Pharmingen, 552178). To assess integrin specificity of the A20 
peptide, biotinylated peptide (Genscript, Hong Kong Ltd) was diluted in PBS supplemented with 
MgCl2 and NaCl (Sigma D8662) and incubated with cells on ice for 20 minutes before being 
stained with streptavadin-PE (LifeTech S866) for a further 20 minutes on ice.  Flow cytometry 
was performed using a FACSCalibur cytometer with CellQuest Pro software or Fortessa 
cytometer with FACSDiva software.  
 
ELISA. Supernatants from tumor/T-cell co-cultures were analyzed using a human IFN or 
human IL2 ELISA Ready-set-go kit (eBiosciences, Hatfield, UK), as described by the 
manufacturers. To assess integrin specificity of the A20 peptide, ELISA plates were coated with 
recombinant αvβ6 (3817-AV-050), αvβ3 (3050-AV-050), αvβ5 (2528-AV-050), αvβ8 (4135-
AV-050) integrin proteins (all R&D systems) in PBS overnight. Wells were washed with PBS 
supplemented with MgCl2 and NaCl (wash buffer) before blocking for 2 hours with 1% w/v milk 
in wash buffer. After washing, 100μl biotinylated peptide was added in 0.1% w/v milk in wash 
buffer for 1 hour followed by washing, and incubation with 100μl 1:500 dilution streptavidin-
HRP (Dako P039701-2) for 1 hour. Plates were then washed and incubated with 100μl hydrogen 
peroxide/tetramethylbenzidine (R&D Substrate Reagent DY999) for 20 minutes before addition 
of 50μl of 2N sulphuric acid. 
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Cytotoxicity assays. Tumor cell monolayers (96 well plate) were incubated with T-cells for 24-
72h at a 1:1 tumor cell: T-cell ratio, unless otherwise indicated. Destruction of tumor cell 
monolayers by T-cells was quantified using an MTT or luciferase assay. In the former, T-cells 
were removed and MTT (Sigma) was added at 500µg/ml in fresh D10 medium for 1-2 hours at 
37°C and 5% CO2. After removal of the supernatant, formazan crystals were re-suspended in 
50μL DMSO. Absorbance was measured at 560nm. In luciferase assays, D-luciferin 
(PerkinElmer) was added at 150μg/ml immediately prior to luminescence reading. Tumor cell 
viability was calculated as (absorbance or luminescence of monolayer cultured with T-cells / 
absorbance or luminescence of untreated monolayer alone) x 100 %. 
 
In vivo studies. All in vivo experimentation adhered to U.K. Home Office guidelines, as 
specified in project license number 70/7794 and was approved by the King’s College London 
animal welfare committee. Where necessary, tumor cells were transduced with SFG ffluc/tdTom 
and were purified by flow sorting prior to engraftment in vivo. SKOV-3 (1 × 106 cells), MDA-
MB-468, Panc0403 or BxPC3 (2 × 106 cells each) were inoculated i.p. into SCID Beige mice. 
Engineered T-cells (1-2 × 107 cells in total as indicated in individual experiments) were 
administered i.p on day 14 (BxPC3, Panc0403), day 21 (SKOV-3) or day 42 (MDA-MB-468). 
Bioluminescence imaging was performed using an IVIS Spectrum Imaging platform 
(PerkinElmer) with Living Image software (PerkinElmer). To image tumor status, mice were 
injected i.p. with D-luciferin (150 mg/kg; PerkinElmer) and imaged under isoflurane anesthesia 
after 12 min. To image T-cells, mice were injected i.p with coelenterazine (30μg/mouse; 
PerkinElmer) and imaged under isoflurane anesthesia after 30 min. Image acquisition was 
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conducted on a 15- or 25-cm field of view with medium binning and auto-exposure. To assess 
safety of CAR T-cells, i.v. bolus doses of 20 million CAR T-cells were administered at the 
indicated intervals, making comparison with PBS. To assess the effect of exogenous 1x105 
BxPC3 cells were inoculated i.p into NSG mice before treatment with 2.5 x 106 T-cells i.p +/- 
hIL-4 (Miltenyi). Interleukin-4 was administered three times weekly i.p thereafter.  In all 
experiments, animals were inspected daily and weighed weekly. Mice were culled if 
symptomatic as a result of tumor progression or weight loss of >20%.  
 
Statistical analysis. For comparison of two groups, datasets were analyzed using two-tailed 
Student’s t test. Survival data were analysed using the Log-rank (Mantel-Cox) test. Correlation 
between intensity of αvβ6 expression and T-cell effector function was determined using Pearson 
r correlation. All statistical analysis was performed using GraphPad Prism version 5.0 or 6.0 
(GraphPad software, San Diego, CA) or Excel for Mac 2011 (Berkshire, UK). 
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FIGURE LEGENDS 
 
Figure 1 Design and integrin specificity of retroviral-encoded CAR constructs. (a) To create 
an αvβ6-specific CAR targeting moiety, the A20 peptide derived from the GH-loop of the capsid 
protein VP1 from Foot and Mouth Disease Virus (serotype 01 BFS) was placed downstream of a 
CD124 signal peptide. A matched but scrambled peptide (named C20) was generated in which 
RGDL was replaced with AAAA. A second αvβ6-specific CAR targeting moiety was engineered 
by placing the B12 peptide downstream of a CD3 signal peptide. (b) Schematic structure of 
αvβ6-specific CARs and (c) matched endodomain-truncated control. (d) Schematic structure of 
4αβ chimeric cytokine receptor in which the IL-4 receptor α ectodomain is fused to the 
transmembrane and endodomain of the shared IL-2/15 receptor β. (e) The SFG retroviral vector 
was used to express CARs in human T-cells. LTR – long terminal repeat; S – signal peptide; T – 
targeting moiety; M – human c-myc epitope tag, recognized by 9e10 antibody. In some 
constructs, equimolar co-expression of the IL-4-responsive 4αβ chimeric cytokine receptor was 
achieved using a Thosea Asigna (T)2A ribosomal skip peptide, placed downstream of a furin 
cleavage site, designed to remove peptide overhangs on the C-terminus of the upstream encoded 
polypeptide. (f) Expression of the indicated integrins in A375 cells as detected by flow 
cytometry. (g) A375 cells were transduced with the pBabe puro retroviral vector (A375 puro) or 
with pBabe puro that encodes for the integrin β6 subunit. Cell surface expression of β6 was 
determined in both cell populations by flow cytometry. SSC – side scatter. (h) A375 puro cells 
(αvβ6-negative) or A375 β6 cells (αvβ6-positive) were co-cultivated at a 1:1 ratio with the 
indicated CAR engineered T-cells in the absence of exogenous cytokine. Data show the mean ± 
SD of residual tumor cell viability from 5 independent experiments, each performed in triplicate. 
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Survival was quantified by MTT assay at 24-168h and expressed relative to untreated tumor cells 
(set at 100% viability). (i) Cells were co-cultivated at a 1:1 ratio with the indicated CAR 
engineered T-cells in the absence of exogenous cytokine for 48hrs. Data show the mean ± SD of 
IFN-γ detected in the cell supernatant from 3 independent experiments, each performed in 
duplicate. (j) Binding of biotinylated A20 peptide to A375 puro cells (αvβ6-negative) or A375 
β6 cells (αvβ6-positive) was detected by flow cytometry. Data show the mean ± SD geometric 
mean fluorescent intensity of 4 independent experiments. (k) Binding of biotinylated A20 
peptide to recombinant integrins was quantified by ELISA. (l) SFG rluc/GFP vector, which co-
expresses Renilla luciferase (red-shifted 8.6-535 variant) with GFP using a furin-T2A (F-T2A) 
intervening sequence. (m) SFG ffluc/tdTom vector, which co-expresses firefly luciferase with 
tdTomato red fluorescent protein using a F-T2A intervening sequence.  
 
Figure 2 In vitro assessment of anti-tumor activity of CAR T-cells targeted against αvβ6. 
Firefly luciferase-expressing pancreatic (a), HER2 amplified breast (b), luminal breast (c), triple 
negative breast (d), or ovarian tumor cells (e) were co-cultivated at a 1:1 ratio with the indicated 
CAR/4αβ-engineered T-cells in the absence of exogenous cytokine, following ex vivo expansion 
and enrichment of CAR T-cells using IL-4. Data show the mean ± SD of residual tumor cell 
viability from 3-12 independent replicates, quantified by MTT assay or by measuring luciferase 
activity at 24-72h. At each time-point, percentage cell survival has been expressed relative to 
untreated tumor cells (set at 100% viability). H – high; I – intermediate; L- low; M – 
minimal/negative expression of αvβ6. 
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Figure 3 Production of IL-2 by αvβ6 re-targeted CAR T-cells. Firefly luciferase-expressing 
pancreatic (a), HER2+ breast (b), luminal breast (c), triple negative breast (d), or ovarian tumor 
cells (e) were co-cultivated at a 1:1 ratio with the indicated CAR/4αβ-engineered T-cells in the 
absence of exogenous cytokine, following ex vivo expansion and enrichment of CAR T-cells 
using IL-4. Supernatant was harvested at each time-point and analyzed for IL-2. Data shows the 
mean ± SD of 3-6 independent replicates. 
 
Figure 4 Relationship between intensity of αvβ6 integrin expression by tumor cells and 
effector function of CAR T-cells. Expression of αvβ6 was determined by flow cytometry and 
then expressed as geometric mean fluorescence intensity (MFI), averaged over 2-8 independent 
experiments. Relationship between MFI of αvβ6 on tumor cells and % tumor cell viability in 
cytotoxicity assays (a), release of IL-2 (b) and release of IFN- (c) by A20-28z/4αβ CAR T-cells 
are depicted graphically, together with Pearson r correlation co-efficient and p (significance) 
values for each time-point and effector parameter. 
 
Figure 5 In vivo anti-tumor activity of αvβ6 re-targeted CAR T-cells against SKOV-3 
ovarian tumor xenografts. (a) T-cells were co-transduced with retroviral vectors encoding for 
rluc/GFP and A20-28z/4αβ or the A20-Tr/4αβ truncated control. After culture for 12 days in IL-
4, cells were analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR 
ectodomain. SSC – side scatter. Quadrants were set using untransduced T-cells cultured in IL-2. 
(b) Mice were injected i.p. with 1 x 106 SKOV-3-ffluc cells and tumors were allowed to establish 
for 21 days before i.p. treatment with 10 x 106 of the indicated gene-modified T-cells. 
Bioluminescence imaging using d-luciferin (substrate for ffluc) was used to monitor tumor 
 30 
status. (c) Data show the mean ± SD of tumor-derived total flux (n=5-8 mice per group). Control 
mice received PBS. The arrow indicates the day of treatment with CAR T-cells. The inset shows 
initial tumor regression on a log scale. ** p<0.01; *** p<0.001 (red – comparing A20-28z v 
PBS; black – comparing A20-28z v A20-Tr). (d) Mice were weighed weekly to assess toxicity of 
CAR T-cells. Data show the mean ± SD of 5-8 mice/group. The arrow indicates the day of 
treatment with CAR T-cells.  
 
Figure 6 In vivo anti-tumor activity of αvβ6 re-targeted CAR T-cells against BxPC3 PDAC 
xenografts. (a) T-cells were co-transduced with retroviral vectors encoding for rluc/GFP and 
A20-28z/4αβ or the A20-Tr/4αβ truncated control. After culture for 12 days in IL-4, cells were 
analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR ectodomain. SSC – side 
scatter. Quadrants were set using untransduced T-cells cultured in IL-2. (b) Mice were injected 
i.p. with 2 x 106 BxPC3-ffluc/tdTom cells and tumors were allowed to establish for 14 days 
before i.p. treatment with 10 x 106 of the indicated gene-modified T-cells. Bioluminescence 
imaging using d-luciferin (substrate for ffluc) was used to monitor tumor status. (c) Data show 
the mean ± SD of tumor-derived total flux (n=5-8 mice per group). Control mice received PBS. 
The arrow indicates the day of treatment with CAR T-cells. The inset shows initial tumor 
regression on a log scale * p<0.02; ** p<0.004; *** p<0.0001 (red – comparing A20-28z v PBS; 
black – comparing A20-28z v A20-Tr). (d) Mice were weighed weekly to assess toxicity of CAR 
T-cells. Data show the mean ± SD % body weight relative to pre-treatment of 5-8 mice/group. 
The arrow indicates the day of treatment with CAR T-cells.  
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Figure 7 In vivo anti-tumor activity of αvβ6 re-targeted CAR T-cells against MDA-MB-468 
breast cancer xenografts. (a) T-cells were co-transduced with retroviral vectors encoding for 
rluc/GFP together with A20-28z/4αβ or the truncated control, A20-Tr/4αβ. After culture for 12 
days in IL-4, cells were analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR 
ectodomain. SSC – side scatter. Quadrants were set using untransduced T-cells cultured in IL-2. 
(b) Mice were injected i.p. with 2 x 106 MDA-MB468-ffluc cells and tumors were allowed to 
establish for 42 days before i.p. treatment with 15 x 106 of the indicated gene-modified T-cells. 
Bioluminescence imaging using d-luciferin (substrate for ffluc) was used to monitor tumor 
status. (c) Data show the mean ± SD of tumor-derived total flux (n=5 mice per group). Control 
mice received PBS. The arrow indicates the day of treatment with CAR T-cells. The inset shows 
initial tumor regression on a log scale ** p<0.003; *** p<0.0003 (red – comparing A20-28z v 
PBS; black – comparing A20-28z v A20-Tr). (d) Mice were weighed weekly to assess toxicity of 
CAR T-cells. Data show the mean ± SD % body weight relative to pre-treatment of 5 
mice/group. The arrow indicates the day of treatment with CAR T-cells.  
 
Figure 8 Imaging of anti-tumor activity and persistence of αvβ6 re-targeted CAR T-cells in 
SCID Beige mice with Panc0403 PDAC xenografts. (a) T-cells were co-transduced with 
retroviral vectors encoding for rluc/GFP together with A20-28z/4αβ or the truncated control, 
A20-Tr/4αβ. After culture for 12 days in IL-4, cells were analyzed by flow cytometry. 9e10 
detects a myc epitope tag in the CAR ectodomain. SSC – side scatter. Quadrants were set using 
untransduced T-cells cultured in IL-2. (b) Mice were injected i.p. with 2 x 106 Panc0403-ffluc 
cells and tumors were allowed to establish for 14 days before i.p. treatment with 10 x 106 of the 
indicated gene-modified T-cells or PBS as control (arrowed). Bioluminescence imaging using d-
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luciferin (substrate for ffluc) was used to monitor tumor status. Data show the mean ± SEM of 
tumor-derived total flux (n=5 mice per group). (c) Mice were weighed weekly to assess toxicity 
of CAR T-cells. Data show the mean ± SEM weight of 5 mice/group. To image T-cells, BLI was 
performed after administration of coelenterazine at the indicated intervals, commencing 1 hour 
after T-cell injection. Images of individual mice (d) and pooled BLI data (mean + SEM, n=5) are 
shown (e).  
 
 
 
 
 
 
 
 
